A patient with type 2 diabetes receives dulaglutide as part of the REWIND trial. This trial demonstrated which primary outcome benefit?

• A Reduction in hospitalisation for heart failure
• B Reduction in progression to end-stage renal disease
• C Reduction in total mortality only
• D Reduction in 3-point major adverse cardiovascular events (MACE) ✓

Explanation

The REWIND trial (2019) evaluated dulaglutide (GLP-1 RA) in T2DM patients with or without prior ASCVD and demonstrated a significant reduction in 3-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke). Notably, REWIND included a majority of patients with cardiovascular risk factors rather than established CVD, broadening the indication. Reduction in heart failure hospitalisation is the primary CV outcome for SGLT2 inhibitors (EMPEROR-Reduced).

Reference: Harrison's Principles of Internal Medicine, 21st ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.